Abstract 40P
Background
Recent evidence suggests that breast cancer may have population-specific characteristics, including differences in the tumour immune microenvironment (TME). Immune cell markers in the TME, particularly CD8, may have utility as predictive and prognostic biomarkers, but there is conflicting evidence from previous studies. The aim of this study was to determine the prognostic utility of immune cell immunohistochemistry markers in tumor samples from a cohort of breast cancer patients from Malaysia.
Methods
We obtained digitized whole slide images of breast tumour tissue samples stained for CD3, CD4, CD8, and PD-L1 markers for 576 breast cancer patients from Subang Jaya Medical Centre, a Malaysian private hospital. These patients were included in the Malaysian Breast Cancer (MyBrCa) study cohort, and thus multi-omics data were also available for analysis for each patient. We also obtained overall survival data from the Malaysian national registry for this group of patients, with a median follow-up time of 68 months.
Results
We compared the intra-tumoral scores for each marker to overall survival data and found that the scores for CD3, CD4, and CD8, but not PD-L1, were positively associated with overall survival, particularly for patients with triple-negative breast cancer (TNBC). Additionally, the CD3, CD4, and CD8 scores were not associated with tumour mutational burden (TMB) or neoantigen load and had a negative correlation with copy number aberrations.
Conclusions
Our results suggest that intra-tumoral markers for T-cells are indicative of good prognosis in Asian breast cancer. Our results also suggest that the TME in Asian breast cancer may be shaped by non-canonical pathways.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Cancer Research Malaysia.
Funding
Cancer Research Malaysia, Yayasan PETRONAS, Yayasan Sime Darby, Scientex Foundation, Estee Lauder Companies, Vistage Malaysia, Newton-Ungku Omar Fund.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
540P - Phase III study of serplulimab plus chemotherapy as first-line therapy for advanced squamous non-small cell lung cancer: ASTRUM-004 Asian subgroup
Presenter: Caicun Zhou
Session: Poster Display
Resources:
Abstract
541P - Integrated analysis of randomized controlled trials IMpower130 and IMpower132 for advanced non-squamous non-small cell lung cancer (NSCLC)
Presenter: Hibiki Udagawa
Session: Poster Display
Resources:
Abstract
542P - First-line HLX07 plus serplulimab with or without chemotherapy versus serplulimab plus chemotherapy in advanced/recurrent squamous non-small cell lung cancer: A phase II study
Presenter: Zhen Wang
Session: Poster Display
Resources:
Abstract
543P - A multicenter retrospective study to investigate risk factors for immune checkpoint inhibitor-induced pneumonitis in non-small cell lung cancer patients with comorbid interstitial pneumonia
Presenter: Yuriko Ishida
Session: Poster Display
Resources:
Abstract
544P - Single cell level investigation of blood cells representing immune checkpoint inhibitor response in lung adenocarcinoma patients
Presenter: Juyong Seong
Session: Poster Display
Resources:
Abstract
545P - Completion of pembrolizumab in advanced non-small cell lung cancer: Real-world outcomes after two years of therapy (COPILOT)
Presenter: Andrew Fantoni
Session: Poster Display
Resources:
Abstract
546P - Combination therapy with anti-PD-1 antibody plus angiokinase inhibitor exerts synergistic antitumor effect against malignant mesothelioma via tumor microenvironment modulation
Presenter: Akio Tada
Session: Poster Display
Resources:
Abstract
547P - Immunotherapy outcome in advanced/metastatic lung cancer patients in real-world experience: Indian data
Presenter: Naveen K
Session: Poster Display
Resources:
Abstract
548P - B-Myb acts as a mentor instant promoter in non-small cell lung cancer by modifying the PD-1/PD-L1 axis
Presenter: Pan Xu
Session: Poster Display
Resources:
Abstract
549P - Drug-induced interstitial lung disease in patients with non-small cell lung cancer treated with immunotherapy for postoperative recurrence: Evaluation of CT findings and histopathological findings of the background lung
Presenter: shodai fujimoto
Session: Poster Display
Resources:
Abstract